Selected article for: "mucosal application and virus infection"
Author: He, Biao; Fu, Yuhong; Xia, Shuai; Yu, Fei; Wang, Qian; Lu, Lu; Jiang, Shibo
Title: Intranasal application of polyethyleneimine suppresses influenza virus infection in mice
  • Document date: 2016_4_27
    • ID: 0rg6n7fr_6
    Snippet: In summary, we demonstrated that PEI, a mucosal stimulant for topical intranasal administration, is highly effective in preventing influenza virus infection. Compared to the bacteria-produced toxin CTB, the chemically synthesized polymer PEI is safer for mucosal application in humans. PEI has been tested in several clinical trials for gene delivery in vivo, demonstrating a good safety profile. 9 Moreover, its low cost of production and abundance .....
    Document: In summary, we demonstrated that PEI, a mucosal stimulant for topical intranasal administration, is highly effective in preventing influenza virus infection. Compared to the bacteria-produced toxin CTB, the chemically synthesized polymer PEI is safer for mucosal application in humans. PEI has been tested in several clinical trials for gene delivery in vivo, demonstrating a good safety profile. 9 Moreover, its low cost of production and abundance makes PEI more suitable for urgent and widespread use during a time of influenza epidemic or pandemic.

    Search related documents:
    Co phrase search for related documents
    • bacteria produce and clinical trial: 1
    • bacteria produce and influenza virus: 1, 2
    • clinical trial and good safety profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • clinical trial and influenza epidemic: 1, 2
    • clinical trial and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and influenza virus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • clinical trial and intranasal administration: 1, 2, 3, 4, 5, 6, 7
    • clinical trial and low cost: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and mucosal application: 1
    • gene delivery and influenza virus: 1, 2, 3, 4, 5, 6, 7
    • gene delivery and influenza virus infection: 1, 2
    • gene delivery and intranasal administration: 1, 2, 3, 4, 5
    • gene delivery and low cost: 1
    • good safety profile and influenza virus: 1
    • good safety profile and intranasal administration: 1, 2
    • good safety profile and low cost: 1, 2
    • influenza epidemic and low cost: 1, 2
    • influenza epidemic and pandemic influenza epidemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • influenza epidemic and pandemic influenza epidemic time: 1, 2